This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current testimonies on nida.nih.gov.
The Federal Responses to the Drug Overdose Epidemic
|
The twin addiction and overdose crises have collided with the COVID-19 pandemic, each exacerbating the deleterious effects of the other
Hearing on Cannabis Policies for the New Decade
|
Chairwoman Eshoo, Ranking Member Burgess, and members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH)...
Marijuana and America’s Health: Questions and Issues for Policy Makers
|
Watch the Senate Caucus on International Narcotics Control hearing Chairman Cornyn, Co-Chairwoman Feinstein and members of the Caucus on International Narcotics Control, we appreciate the opportunity to share the content...
Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives
|
Testimony by Dr. Nora Volkow, NIDA Director and others to the House Committee on Energy and Commerce
The Federal Response to the Opioid Crisis
|
Testimony by Dr. Francis Collins, NIH Director and others before the Senate Committee on Health, Education, Labor & Pensions
Research on the Use and Misuse of Fentanyl and Other Synthetic Opioids
|
Testimony by Wilson M. Compton, M.D., Deputy Director, National Institute on Drug Abuse before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
Fiscal Year 2017 Budget Request
|
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the House Subcommittee on Labor-HHS-Education Appropriations
Researching the Potential Medical Benefits and Risks of Marijuana
|
Testimony by Susan R.B. Weiss, Ph.D. - Director, Division of Extramural Research, National Institute on Drug Abuse, before the Senate Judiciary Committee, Subcommittee on Crime and Terrorism
What Science tells us About Opioid Abuse and Addiction
|
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the Senate Judiciary Committee
Fiscal Year 2016 Budget Request
|
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the House Subcommittee on Labor-HHS-Education Appropriations
The Biology and Potential Therapeutic Effects of Cannabidiol
|
Testimony by Nora D. Volkow, Director, National Institute on Drug Abuse, before the Senate Caucus on International Narcotics Control
What is the Federal Government Doing to Combat the Opioid Abuse Epidemic?
|
Testimony by Nora D. Volkow, Director, National Institute on Drug Abuse, before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
Fiscal Year 2015 Budget Request
|
Mr. Chairman and Members of the Committee: I am pleased to present the Fiscal Year (FY) 2015 President’s Budget Request for the National Institute on Drug Abuse (NIDA). The FY...
Mixed Signals: The Administration’s Policy on Marijuana, Part Four -- Scientific Focus on the Adverse Health Effects of Marijuana Use
|
Mr. Chairman and Members of the Subcommittee. Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to participate in...
America’s Addiction to Opioids: Heroin and Prescription Drug Abuse
|
Senate Caucus on International Narcotics Control hearing America’s Addiction to Opioids: Heroin and Prescription Drug Abuse (United States Senate Caucus on International Narcotics Control) Good Morning, Madam Chair and members...
Prescription Opioid and Heroin Abuse
|
Good Morning, Mr. Chairman and Members of the Subcommittee. Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to...
Harnessing the Power of Science to Inform Substance Abuse and Addiction Policy and Practice
|
Mr. Chairman and Members of the Subcommittee: Thank you for inviting the National Institute on Drug Abuse, a component of the National Institutes of Health (NIH), to comment on the...
Dangerous Synthetic Drugs
|
Senate Caucus on International Narcotics Control to Hold Hearing on Dangerous Synthetic Drugs (United States Senate Caucus on International Narcotics Control) Introduction Madame Chairwoman and Members of the Caucus: Thank...
Fiscal Year 2013 Budget Request
|
Introduction Mr. Chairman and Members of the Committee: I am pleased to present the President’s budget request for the National Institute on Drug Abuse (NIDA) of the National Institutes of...
Fiscal Year 2012 Budget Request
|
Introduction Mr. Chairman and Members of the Committee: I am pleased to present the President's Fiscal year 2012 Budget Request for the National Institute on Drug Abuse (NIDA). The FY...
Prescription Drug Abuse
|
Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), an agency of the Department of Health and Human Services...
Treating Addiction as a Disease: The Promise of Medication-Assisted Recovery
|
Mr. Chairman and Members of the Subcommittee, as the Director of the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, an agency of the Department...
Fiscal Year 2011 Budget Request
|
Introduction Drug abuse and addiction are a major burden to society, with economic costs alone estimated to exceed $600 billion annually in the United States (ONDCP 2004; Rehm et al...
Fiscal Year 2010 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's Fiscal Year 2010 Budget request for the National Institute on Drug Abuse...
Restoring Fairness to Federal Sentencing: Addressing the Crack-Powder Disparity
|
Statement for the Record Thank you, Mr. Chairman and members of the Subcommittee, for the opportunity to contribute to this important discussion. The National Institute on Drug Abuse (NIDA), a...
Scientific Research on Prescription Drug Abuse
|
Mr. Chairman, Members of the Subcommittee, and Members of the Caucus: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
Fiscal Year 2009 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's Budget for the National Institute on Drug Abuse (NIDA) of the National...
Scientific Research on the Scope, Pharmacology, and Health Consequences of Cocaine Abuse and Addiction
|
Thank you, Mr. Chairman and members of the Subcommittee, for the opportunity to contribute to this important discussion. I am Dr. Nora Volkow, Director of the National Institute on Drug...
Fiscal Year 2008 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Subcommittee: I am pleased to present the Fiscal Year (FY) 2008 President's budget request for the National Institute on Drug...
Public Hearing on the Scope, Pharmacology and Health Consequences of Cocaine Abuse and Addiction
|
Thank you for allowing science to play a central role in this discussion. I am Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), a component of...
Efforts of the National Institute on Drug Abuse to Prevent and Treat Prescription Drug Abuse
|
Statement for the Record Mr. Chairman and Members of the Subcommittee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
Availability and Effectiveness of Programs to Treat Methamphetamine Abuse
|
Statement for the Record Mr. Chairman and Members of the Committee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
Fiscal Year 2007 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Subcommittee: I am pleased to present the Fiscal Year (FY) 2007 President's budget request for the National Institute on Drug...
An Examination of Drug Treatment Programs Needed to Ensure Successful Re-entry
|
Statement for the Record Mr. Chairman and Members of the Committee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
Medications Development Research for Treatment of Amphetamine and Methamphetamine Addiction - Report to Congress
|
Download this report (PDF, 304KB) Introduction In compliance with Section 3633 of the Children's Health Act of 2000, Public Law 106-310, as amended by section 2502 of the 21st Century...
Substance Abuse and Mental Health Research and Services
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to be here to present the President's fiscal year (FY) 2006 budget request for the National...
Methamphetamine Abuse
|
Statement for the Record Mr. Chairman and Members of the Committee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
Fiscal Year 2006 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the Fiscal Year (FY) 2006 President's budget request for the National Institute on Drug...
Consequences of the Abuse of Anabolic Steroids
|
Statement for the Record Mr. Chairman and members of the Committee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
Fiscal Year 2005 Budget Request - Substance Abuse and Mental Health
|
Statement for the Record Mr. Chairman and Members of the Committee, I am pleased to be here to present the President's fiscal year (FY) 2005 budget request for the National...
Marijuana and Medicine: The Need for a Science-Based Approach
|
Statement for the Record Chairman Souder and Members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
Fiscal Year 2005 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's budget request for the National Institute on Drug Abuse. The fiscal year...
Measuring the Effectiveness of Drug Addiction Treatment
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA) to participate in this important hearing. I am...
Fiscal Year 2004 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's budget request for the National Institute on Drug Abuse. The fiscal year...
Research on MDMA
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, thank you for the opportunity to present scientific findings about Ecstasy or MDMA. I am Dr. Glen Hanson, the...
Oversight Hearing on the Office of National Drug Control Policy's National Youth Anti-Drug Media Campaign
|
Statement for the Record Mr. Chairman and members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA) to participate in this important hearing, which will...
Fiscal Year 2003 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's budget request for the National Institute on Drug Abuse for FY 2003...
OxyContin: Balancing Risks and Benefits
|
Statement for the Record Mr. Chairman and Members of the Committee, I am pleased to submit the following statement for the record discussing what we have come to learn about...
Looking the Other Way: Rave Promoters and Club Drugs
|
Statement for the Record Mr. Chairman and distinguished members of the Caucus, thank you for inviting the National Institute on Drug Abuse (NIDA) to participate in this important and timely...
Evaluation of the Office of National Drug Control Policy's (ONDCP's) National Youth Anti-Drug Media Campaign
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, I am Susan David, Deputy Chief of the Prevention Research Branch at the National Institute on Drug Abuse (NIDA)...
Ecstasy Abuse and Control
|
Statement for the Record Mr. Chairman, and Members of the Committee, thank you for inviting me to participate in this important and timely hearing on MDMA. I am pleased with...
Continuing Concern Over Imported Pharmaceuticals
|
Summary Statement Many substances can be very effective medications when used properly, but highly addictive, dangerous, substances when misused. Morphine exemplifies this point. Morphine is a powerfully addictive drug. However...
Fiscal Year 2002 Budget Request
|
Mr. Chairman, and Members of the Committee: Statement for the Record I am pleased to present the President's budget request for the National Institute on Drug Abuse, a sum of...
Treatment, Education, and Prevention: Adding to the Arsenal in the War on Drugs
|
Mr. Chairman, and Members of the Committee, it is a great pleasure to be here today to share with you what we have been learning from science about the nature...
U.S. Senate Caucus on International Narcotics Control
|
Statement for the Record Mr. Chairman and distinguished members of the Caucus, thank you for allowing the National Institute on Drug Abuse (NIDA) to submit a formal statement for the...
Programs of the Substance Abuse and Mental Health Services Administration (SAMHSA) and SAMHSA Coordination with the National Institute on Drug Abuse
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, thank you for inviting me to participate in this hearing. I am pleased to have this opportunity to tell...
Fiscal Year 2001 Budget Request
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's non-AIDS budget request for the National Institute on Drug Abuse (NIDA) for...
Heroin Abuse and Addiction
|
Statement for the Record Thank you for inviting me to participate in this important hearing. I am Dr. Alan I. Leshner, the Director of the National Institute on Drug Abuse...
The Drug Addiction Treatment Act of 1999
|
Statement for the Record There is a tremendous need to develop new and effective medications for drug addiction and to increase access to treatment. This is articulated by a number...
Drug Legalization
|
Statement for the Record Thank you for inviting me to participate in this hearing. What I would like to do this morning is illustrate through the use of some recent...
Science-Based Approaches to Preventing and Treating Heroin Abuse and Addiction
|
Statement for the Record Mr. Chairman and Members of the Committee: I am Dr. Timothy P. Condon, Associate Director of the National Institute on Drug Abuse (NIDA), one of the...
Hearing on Youth Media Campaign
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to be here with my distinguished colleagues to discuss the role of the National Institute on...
Formal Statement on NIDA Research
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to be part of this distinguished panel to share with you what science has come to...
Statement on GHB
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, I am Dr. Stephen Zukin, Director of the Division of Clinical and Services Research at the National Institute on...
Fiscal Year 2000 Budget Request
|
Statement of the Director Mr. Chairman and Members of the Committee: I am pleased to present the President's budget request for the National Institute on Drug Abuse for Fiscal Year...
Methadone and the Treatment of Heroin Addiction
|
Statement for the Record Mr. Chairman and Members of the Committee: I am Dr. James Cooper, Associate Director for Medical Affairs, Division of Clinical and Services Research at the National...
Fiscal Year 1999 Budget Request
|
The President in his FY 1999 budget has proposed that the National Institute on Drug Abuse receive $395.1 million, an increase of $35.3 million over the comparable 1998 appropriation. Including the estimated allocation for AIDS, total support provided for NIDA is $576.3 million an increase of $49.1 million over the FY 1998 appropriation. Funds for NIDA efforts in AIDS research are included within the Office of AIDS Research budget request.
Statement on Nicotine
|
Statement of the Director Mr. Chairman and Members of the Committee, I am pleased to be here with my distinguished colleagues to discuss current research findings and future research directions...
Statement on Children's Health Issues
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, I am pleased to be here with my distinguished colleagues to discuss current research findings and future research directions...
Formal Statement - Research supported by the National Institute on Drug Abuse
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, I am pleased to share some very exciting scientific findings with you today and to tell you about our...